InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: cheynew post# 271049

Saturday, 08/27/2016 8:35:26 PM

Saturday, August 27, 2016 8:35:26 PM

Post# of 345745
still analyzing that...

But Foundation Medicine vs Guardant Health gives some clues..
http://www.businessinsider.com/foundation-medicine-suing-guardant-health-2016-5

This 2nd round of combo IO will stress biomarkers and exosomes/proteins/ratios etc are all about biomarkers and quick FDA approvals based on these new up and coming biomarkers

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News